E9KL36 (E9KL36_HUMAN) Homo sapiens (Human)
Transthyretin UniProtKBInterProInteractive Modelling
147 aa; Sequence (Fasta) ;
1 identical sequence: Homo sapiens: P02766
It is possible new templates exist for this target since these models were created.
Available Structures
400 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| The structure of human retinol binding protein with its carrier protein transthyretin reveals inter… |
Heteromer P02753; P02766; | 2×RTL; | ||||
| Assess | ||||||
| Complex of TTR and RBP4 and Oleic Acid |
Heteromer P02753; P02766; | 11×SO4; 2×OLA; | ||||
| Assess | ||||||
| RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN |
Heteromer P02753; P02766; | 2×REA; | ||||
| Assess | ||||||
| Crystal structure of the transthyretin-retinol binding protein-Fab complex |
Heteromer P02753; P02766; | 2×RTL; | ||||
| Assess | ||||||
| Atomic-resolution structure of a cross-beta protofilament | homo-16-mer | |||||
| Assess | ||||||
| Cryo-EM structure of a twisted-dimer transthyretin amyloid fibril from vitreous body of the eye | homo-14-mer | |||||
| Assess | ||||||
| transthyritin derived amyloid fibril from patient with hereditary V30M ATTR amyloidosis | homo-11-mer | |||||
| Assess | ||||||
| Crystal Structure of TTR-G67R | homo-8-mer | |||||
| Assess | ||||||
| Wild type ATTR amyloid fibril from senile systemic amyloidosis | homo-7-mer | |||||
| Assess | ||||||
| ATTRG47E amyloid fibril from hereditary ATTR amloidosis | homo-6-mer | |||||
| Assess | ||||||
| ATTRV20I amyloid fibril from hereditary ATTR amloidosis | homo-6-mer | |||||
| Assess | ||||||
| ATTRV122I amyloid fibril from hereditary ATTR amloidosis | homo-6-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, wild-ty… | homo-5-mer | |||||
| Assess | ||||||
| Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| Cryo-EM structure of wild-type transthyretin amyloid from heart tissue | homo-5-mer | |||||
| Assess | ||||||
| Cardiac amyloid fibrils extracted from a wild-type ATTR amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a wild-type amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a variant ATTR P24S amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient | homo-5-mer | |||||
| Assess | ||||||
| THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME… | homo-4-mer | |||||
| Assess | ||||||
| THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME… | homo-4-mer | |||||
| Assess | ||||||
| THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30ME… | homo-4-mer | |||||
| Assess | ||||||
| TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR… | homo-4-mer | |||||
| Assess | ||||||
| TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR… | homo-4-mer | |||||
| Assess | ||||||
| TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR… | homo-4-mer | |||||
| Assess | ||||||
| TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR… | homo-4-mer | |||||
| Assess | ||||||
| TRANSTHYRETIN (DEL VAL122) | homo-4-mer | |||||
| Assess | ||||||
| TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBR… | homo-4-mer | |||||
| Assess | ||||||
| STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROM… | homo-4-mer | 4×MIL; | ||||
| Assess | ||||||
| TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINE | homo-4-mer | 4×P28; | ||||
| Assess | ||||||
| TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4) | homo-4-mer | 2×SO4; 4×T44; | ||||
| Assess | ||||||
| MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN … | homo-4-mer | 4×T33; | ||||
| Assess | ||||||
| Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4a… | homo-4-mer | 4×T4A; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROX… | homo-4-mer | 8×FL9; | ||||
| Assess | ||||||
| High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1… | homo-4-mer | 4×PCQ; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 16-alpha-bromo-estradiol | homo-4-mer | 4×ESZ; 4×EDO; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with ferulic acid and curcumin. | homo-4-mer | 2×CUR; 2×NA; 2×EDO; 4×FER; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with curcumin | homo-4-mer | 4×CUR; 2×NA; 2×EDO; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)ethanoic acid | homo-4-mer | 4×ES8; 2×EDO; | ||||
| Assess | ||||||
| Dual binding mode for 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid binding to Human transthyretin… | homo-4-mer | 4×7BD; 4×EDO; | ||||
| Assess | ||||||
| Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effects | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG) | homo-4-mer | 6×KDH; 2×GOL; | ||||
| Assess | ||||||
| Neutron structure of human transthyretin (TTR) at room temperature to 2.3A resolution (monochromati… | homo-4-mer | |||||
| Assess | ||||||
| Neutron structure of human transthyretin (TTR) at room temperature to 2.0A resolution (Laue) | homo-4-mer | |||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 4-hydroxy-chalcone | homo-4-mer | 3×IPJ; | ||||
| Assess | ||||||
| Human transthyretin covalently modified with A2-derived stilbene in the compressed conformation | homo-4-mer | 2×1WZ; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with pinostilbene | homo-4-mer | 4×8KZ; 4×NA; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 2 | homo-4-mer | 4×TQ0; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE of HUMAN TRANSTHYRETIN IN COMPLEX WITH LUTEOLIN AT 1.1 A RESOLUTION | homo-4-mer | 4×LU2; 6×GOL; 2×NA; | ||||
| Assess | ||||||
| Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethy… | homo-4-mer | 4×1W3; | ||||
| Assess | ||||||
| Structure of human transthyretin in complex with Tolcapone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Crystal structure of Human Transthyretin at 1.15 Angstrom resolution | homo-4-mer | 4×NA; | ||||
| Assess | ||||||
| V30G Transthyretin structure in complex with Tolcalpone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acid | homo-4-mer | 4×1WZ; | ||||
| Assess | ||||||
| The Structure of V122I Mutant Transthyretin in Complex with AG10 | homo-4-mer | 4×16V; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 3-O-methyltolcapone analogue 1 | homo-4-mer | 4×U1F; | ||||
| Assess | ||||||
| Crystal structure of human wild type transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)-(3… | homo-4-mer | 4×AQI; | ||||
| Assess | ||||||
| The Structure of V122I Mutant Transthyretin in Complex with Tafamidis | homo-4-mer | 2×3MI; | ||||
| Assess | ||||||
| Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting … | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with Perfluorooctanoic acid (PFOA) | homo-4-mer | 4×8PF; 2×NA; | ||||
| Assess | ||||||
| Structure of human transthyretin mutant A109V | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with 3-deoxytolcapone, a tolcapone analogue | homo-4-mer | 4×LVB; | ||||
| Assess | ||||||
| X-ray structure of TTR mutant - T119M at 1.22A resolution | homo-4-mer | |||||
| Assess | ||||||
| X-ray structure of perdeuterated TTR mutant - T119M at 1.22A | homo-4-mer | |||||
| Assess | ||||||
| Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-di… | homo-4-mer | 4×0UC; | ||||
| Assess | ||||||
| Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-… | homo-4-mer | 4×18J; | ||||
| Assess | ||||||
| X-ray structure of TTR mutant - S52P at 1.23A resolution | homo-4-mer | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolution | homo-4-mer | 4×7LU; 2×NA; 2×GOL; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid in a dual b… | homo-4-mer | 4×6BD; 4×GOL; | ||||
| Assess | ||||||
| Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone | homo-4-mer | 4×3M1; | ||||
| Assess | ||||||
| High resolution crystal structure of human transthyretin bound to ligand and conjugates of 3-(5-(3,… | homo-4-mer | 4×4AJ; | ||||
| Assess | ||||||
| Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei… | homo-4-mer | 4×SO4; 4×R3X; 2×DMS; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with Perfluoroktansulfonsyra (PFOS) | homo-4-mer | 4×P8S; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 3-O-methyltolcapone, a tolcapone analogue | homo-4-mer | 4×LVE; | ||||
| Assess | ||||||
| Wild Type Human Transthyretin pH 7.5 | homo-4-mer | 4×CA; | ||||
| Assess | ||||||
| X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolution | homo-4-mer | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue | homo-4-mer | 4×JTE; | ||||
| Assess | ||||||
| Structure of human transthyretin mutant A108V | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTION | homo-4-mer | |||||
| Assess | ||||||
| X-ray structure of wild-type TTR at 1.30A resolution | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with CHF5075, a flurbiprofen analogue | homo-4-mer | 4×JTN; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid. | homo-4-mer | 2×5JW; | ||||
| Assess | ||||||
| Transthyretin in complex with a covalent small molecule kinetic stabilizer | homo-4-mer | 4×A93; | ||||
| Assess | ||||||
| Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei… | homo-4-mer | 4×SO4; 4×R4G; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolution | homo-4-mer | 4×6B5; 2×NA; | ||||
| Assess | ||||||
| High resolution crystal structure of human transthyretin bound to ligand and conjugates of 4-(5-(3,… | homo-4-mer | 4×2WN; 2×4B8; | ||||
| Assess | ||||||
| Complex of Transthyretin with resveratrol exhibits multiple binding modes | homo-4-mer | 4×STL; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamide | homo-4-mer | 4×16L; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin mutant T119M at pH 5.5 | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 | homo-4-mer | 15×ZN; 12×ACT; 3×GOL; | ||||
| Assess | ||||||
| Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei… | homo-4-mer | 4×SO4; 4×R3S; 2×DMS; | ||||
| Assess | ||||||
| Crystal structure of Transthyretin-quercetin complex | homo-4-mer | 4×DMS; 2×QUE; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with oxyresveratrol | homo-4-mer | 6×EZE; 4×NA; | ||||
| Assess | ||||||
| Crystal Structure Of Human Transthyretin in complex with 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) | homo-4-mer | 4×F52; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with Quercetin 3-O-beta-D-galactoside | homo-4-mer | 2×EDO; 2×J6O; 2×IMD; | ||||
| Assess | ||||||
| Structure of transthyretin in complex with the kinetic stabilizer 201 | homo-4-mer | 4×IIH; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with alpha-mangostin | homo-4-mer | 4×MKS; 4×CL; 2×CA; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with isorhapontigenin | homo-4-mer | 4×P5O; 4×NA; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA) | homo-4-mer | 4×XDI; 2×NA; | ||||
| Assess | ||||||
| Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4… | homo-4-mer | 4×0UA; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acid | homo-4-mer | 2×L32; 2×DMS; | ||||
| Assess | ||||||
| X-ray structure of perdeuterated wild-type TTR at 1.42A resolution | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of DACM wild type Transthyretin | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Ser85Pro Mutant | homo-4-mer | 2×NA; 2×CL; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin double mutant K35T/T119M | homo-4-mer | |||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Hydroxyphenyl)ethenyl]benzoic Acid | homo-4-mer | 4×XOS; | ||||
| Assess | ||||||
| Structure of human transthyretin mutant A108I | homo-4-mer | |||||
| Assess | ||||||
| Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-… | homo-4-mer | 4×18A; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with CHF4795, a flurbiprofen analogue | homo-4-mer | 4×JTK; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with 2,2',4,4'-tetrahydroxybenzophenone (BP2) | homo-4-mer | 4×27M; 2×NA; 2×GOL; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazole | homo-4-mer | 4×3M3; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]benzoic Acid | homo-4-mer | 4×XLB; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with Clonixin | homo-4-mer | 4×6J3; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of wild-type transthyretin in complex with rafoxanide | homo-4-mer | 4×OX9; 4×NA; | ||||
| Assess | ||||||
| Crystal structure of transthyretin mutant A25T in complex with CHF5074, a flurbiprofen analogue | homo-4-mer | 4×H50; 4×PO4; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with 2,6-Dinitro-p-cresol (DNPC) | homo-4-mer | 4×6J1; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with gamma-mangostin | homo-4-mer | 4×MKT; 8×CL; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 5-[(1E)-2-(4-Boronic acid)ethenyl]-1,3-benzenediol | homo-4-mer | 4×S4B; | ||||
| Assess | ||||||
| Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei… | homo-4-mer | 4×D75; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole | homo-4-mer | 4×3M4; | ||||
| Assess | ||||||
| Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylami… | homo-4-mer | 4×1W4; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acid | homo-4-mer | 4×L57; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 1,1'-(1E)-(1,2-Ethenediyl)bis[2-chloro-4-boronic acid]benze… | homo-4-mer | 4×IWW; | ||||
| Assess | ||||||
| Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and thei… | homo-4-mer | 4×G7G; | ||||
| Assess | ||||||
| Complex of Human Transthyretin with 3',5'-Dichlorophenylanthranilic Acid | homo-4-mer | 4×FQ7; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene | homo-4-mer | 4×LJ2; | ||||
| Assess | ||||||
| Human Transthyretin Ser52Pro Mutant | homo-4-mer | 4×CA; | ||||
| Assess | ||||||
| Crystal structure of TTR/resveratrol/T4 complex | homo-4-mer | 2×T44; 2×STL; | ||||
| Assess | ||||||
| Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1) | homo-4-mer | 4×B72; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acid | homo-4-mer | 4×30Z; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 3-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]benzoic Acid | homo-4-mer | 4×XLO; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin double mutant R34G/T119M at pH 5.5 | homo-4-mer | |||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (R)-3-(9H-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsul… | homo-4-mer | 4×48R; 4×GOL; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with 3,5,6-Trichloro-2-pyridinyloxyacetic acid … | homo-4-mer | 4×SBK; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of transthyretin variant V20S | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acid | homo-4-mer | 4×PWK; | ||||
| Assess | ||||||
| Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR) | homo-4-mer | 20×EDO; 4×NAR; 2×CA; | ||||
| Assess | ||||||
| Transthyretin conjugated with a tafamidis derivative | homo-4-mer | 4×OIT; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Lys15Trp Mutant | homo-4-mer | |||||
| Assess | ||||||
| A25T Transthyretin structure in complex with Tolcalpone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Crystal Structure Of Human Transthyretin in complex with 3,5,6-trichloro-2-pyridinol (TC2P) | homo-4-mer | 8×F4Z; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212 | homo-4-mer | |||||
| Assess | ||||||
| Structure of human transthyretin mutant E89K | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of the apo form of human wild-type transthyretin | homo-4-mer | |||||
| Assess | ||||||
| Structure of transthyretin pathogenic mutation A120S | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with 4,4'-Dihydroxydiphenyl sulfone (Bisphenol … | homo-4-mer | 4×6JD; 2×NA; | ||||
| Assess | ||||||
| Probing the dissociation pathway of a kinetically labile transthyretin mutant (A25T) | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of V30G mutated human transthyretin | homo-4-mer | 4×MG; | ||||
| Assess | ||||||
| Crystal structure of V30L mutated human transthyretin | homo-4-mer | 4×MG; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A25T - #1 | homo-4-mer | 4×PGE; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with CHF5074 at neutral pH | homo-4-mer | 4×H50; | ||||
| Assess | ||||||
| Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pH | homo-4-mer | 4×H50; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with diflunisal at acidic pH | homo-4-mer | 4×1FL; | ||||
| Assess | ||||||
| transthyretin with tethered inhibitor on one monomer. | homo-4-mer | 4×P2C; | ||||
| Assess | ||||||
| Human TTR altered by a rhenium tris-carbonyl Pyta-C8 derivative | homo-4-mer | 4×DMS; 6×EDO; 6×ACT; 4×RE; 2×IMD; | ||||
| Assess | ||||||
| Crystal structure of DACM F87M/L110M Transthyretin mutant | homo-4-mer | 3×CL; 4×ACT; | ||||
| Assess | ||||||
| Structure of human transthyretin complex with analgesic inhibitor | homo-4-mer | 4×FQ7; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of the transthyretin mutant TTR C10A/Y114C | homo-4-mer | 12×BME; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant V30M in complex with luteolin | homo-4-mer | 4×LU2; 2×NA; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 3-[(1E)-2-(4-Boronic acid)ethenyl]benzoic Acid | homo-4-mer | 4×XBS; | ||||
| Assess | ||||||
| Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two… | homo-4-mer | |||||
| Assess | ||||||
| The crystal structure of 2,4-dinitrophenol in complex with human transthyretin | homo-4-mer | 4×SO4; 4×DNF; | ||||
| Assess | ||||||
| Y114C Transthyretin structure in complex with Tolcalpone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with iododiflunisal | homo-4-mer | 4×FHI; | ||||
| Assess | ||||||
| V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24) | homo-4-mer | 4×GOL; 4×G24; | ||||
| Assess | ||||||
| Crystal structure of Human Transthyretin (E54G) | homo-4-mer | 6×GOL; 4×SO4; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (E)-3-(((4-hydroxybenzylidene)amino)oxy)propanoic acid | homo-4-mer | 4×NEK; | ||||
| Assess | ||||||
| Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR) | homo-4-mer | 4×57D; | ||||
| Assess | ||||||
| V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1) | homo-4-mer | 4×B72; 6×GOL; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant C10A/M13V | homo-4-mer | 6×CA; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Val30Met Mutant | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin in Complex with Gemfibrozil | homo-4-mer | 4×4TX; 2×NA; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-5,5'-(ethene-1,2-diyl)bis(1,1-dihydroxy-3-oxo-1,3-dihydrobenzo[c]… | homo-4-mer | 4×S2B; | ||||
| Assess | ||||||
| Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5 | homo-4-mer | 12×ZN; 7×GOL; 6×ACT; | ||||
| Assess | ||||||
| Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5 | homo-4-mer | 12×ZN; 10×ACT; 7×GOL; | ||||
| Assess | ||||||
| Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soaked | homo-4-mer | 12×ZN; 6×ACT; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl ester | homo-4-mer | 4×0XR; 2×CA; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl … | homo-4-mer | 4×PWH; 4×CA; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A25T - #2 | homo-4-mer | 2×PGE; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 2-Boronic Acid-1-[(1E)-2-(3-boronic acid)ethenyl]-4-chlorob… | homo-4-mer | 4×7UV; | ||||
| Assess | ||||||
| Structure of human transthyretin complexed with bromophenols: a new mode of binding | homo-4-mer | 4×GOL; 4×PBR; | ||||
| Assess | ||||||
| Structure of human transthyretin complexed with bromophenols: a new mode of binding | homo-4-mer | 4×TBP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18 | homo-4-mer | 4×HKA; | ||||
| Assess | ||||||
| Crystal structure of transthyretin mutant I84S at PH 7.5 | homo-4-mer | |||||
| Assess | ||||||
| Human TTR crystals soaked in manganese chloride. | homo-4-mer | 4×MN; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17 | homo-4-mer | 4×FT0; | ||||
| Assess | ||||||
| Crystal structure of transthyretin variant L58H at acidic pH | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of V30I mutated human transthyretin | homo-4-mer | 4×MG; | ||||
| Assess | ||||||
| Human TTR altered by a rhenium tris-carbonyl Pyta-C12 derivative | homo-4-mer | 4×EDO; 2×PEG; 6×RE; 2×ACT; 2×DMS; 2×IMD; | ||||
| Assess | ||||||
| Crystal structure of transthyretin variant L55P at neutral pH | homo-4-mer | |||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic aci… | homo-4-mer | 4×6BD; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin at pH 4.6 | homo-4-mer | |||||
| Assess | ||||||
| X-ray structure of human transthyretin (TTR) at room temperature to 1.9A resolution | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate | homo-4-mer | 6×5NS; | ||||
| Assess | ||||||
| Crystal structure of transthyretin variant L55P at acidic pH | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with 3-isomangostin | homo-4-mer | 4×MKU; | ||||
| Assess | ||||||
| Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT) | homo-4-mer | 4×LU2; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin with bound chloride | homo-4-mer | 12×CL; | ||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-boronic acid)ethenyl]-1,3-benzenediol | homo-4-mer | 4×7VG; | ||||
| Assess | ||||||
| Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5 | homo-4-mer | 12×ZN; 7×ACT; 4×GOL; | ||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin in complex with sulindac | homo-4-mer | 4×SUZ; | ||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin in complex with sulindac | homo-4-mer | 4×SUZ; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4) | homo-4-mer | 4×T44; | ||||
| Assess | ||||||
| Structure of human transthyretin complexed with bromophenols: a new mode of binding | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of human transthyretin - wild type | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API) | homo-4-mer | 4×AGI; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of transthyretin mutant 87-110-117 | homo-4-mer | |||||
| Assess | ||||||
| V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5 | homo-4-mer | 4×GEN; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin (E54K) | homo-4-mer | 10×GOL; 2×SO4; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATURE | homo-4-mer | 12×BME; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with lumiracoxib | homo-4-mer | 4×LUR; | ||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin in complex with indomethacin | homo-4-mer | 4×IMN; | ||||
| Assess | ||||||
| Crystal structure of Human Transthyretin (wild-type) | homo-4-mer | 4×SO4; 6×GOL; | ||||
| Assess | ||||||
| Structure of transthyretin L55P in complex with Zn | homo-4-mer | 8×ZN; 4×CAC; | ||||
| Assess | ||||||
| Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24) | homo-4-mer | 4×G24; | ||||
| Assess | ||||||
| Transthyretin natural mutant A25T | homo-4-mer | |||||
| Assess | ||||||
| Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE) | homo-4-mer | 4×KMP; | ||||
| Assess | ||||||
| Structure of transthyretin synthetic mutation A120L | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of human wild-type transthyretin in complex with diclofenac | homo-4-mer | 4×DIF; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with indomethacin | homo-4-mer | 4×IMN; | ||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin in complex with sulindac | homo-4-mer | 4×SUZ; | ||||
| Assess | ||||||
| Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2 | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of wild-type human transthyretin in complex with lumiracoxib | homo-4-mer | 4×LUR; | ||||
| Assess | ||||||
| Crystal structure of transthyretin mutant I84A at neutral pH | homo-4-mer | |||||
| Assess | ||||||
| Wild-type Transthyretin in complex with 5-[(1E)-2-(2-Chloro-4-hydroxyphenyl)ethenyl]-1,3-benzenediol | homo-4-mer | 4×S2L; | ||||
| Assess | ||||||
| Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated prote… | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin variant V30M at acidic pH | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55S | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin variant Y114H | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin variant Y114H at acidic pH | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin variant T60A at acidic pH | homo-4-mer | 2×ACT; | ||||
| Assess | ||||||
| Human TTR altered conformation from soaking in CuCl2. | homo-4-mer | 6×CU; 2×PEG; 2×ACT; 2×EDO; | ||||
| Assess | ||||||
| Human TTR altered conformation from soaking in iron chloride. | homo-4-mer | 6×ACT; 2×FFE; 10×FE; | ||||
| Assess | ||||||
| LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE | homo-4-mer | |||||
| Assess | ||||||
| MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4) | homo-4-mer | 2×T44; | ||||
| Assess | ||||||
| Neutron structure of human transthyretin (TTR) S52P mutant at room temperature to 1.8A resolution (… | homo-4-mer | |||||
| Assess | ||||||
| Neutron structure of human transthyretin (TTR) T119M mutant at room temperature to 1.85A resolution | homo-4-mer | |||||
| Assess | ||||||
| Neutron and X-ray joint structure of WT-TTR in complex with piceatannol | homo-4-mer | 4×PIT; | ||||
| Assess | ||||||
| Neutron structure of human transthyretin (TTR) S52P mutant in complex with tafamidis at room temper… | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 4-chloro-9,10-dioxo-9,10-dihydroanthracene… | homo-4-mer | 4×CA; 4×HG6; | ||||
| Assess | ||||||
| Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acid | homo-4-mer | 4×CJZ; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carboxylic ac… | homo-4-mer | 4×CA; 4×HH9; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with 4-chloro-9-oxo-9H-xanthene-2-carbox… | homo-4-mer | 4×CA; 4×HH9; | ||||
| Assess | ||||||
| Crystal structure of E61K mutated transthyretin | homo-4-mer | 2×CA; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazole | homo-4-mer | 4×MR4; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with purpurin | homo-4-mer | 2×9TF; | ||||
| Assess | ||||||
| Transthyretin in complex with 5-(4-nitrophenylazo)-3-iodosalicylic acid | homo-4-mer | 4×BQB; | ||||
| Assess | ||||||
| Structure of wild-type TTR in complex with tafamidis | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with piceatannol | homo-4-mer | 4×PIT; 2×NA; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenz… | homo-4-mer | 4×DZ3; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamide | homo-4-mer | 4×DZ2; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)aniline | homo-4-mer | 4×IW6; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with apigenin | homo-4-mer | 4×AGI; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide | homo-4-mer | 4×DZ1; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with pterostilbene | homo-4-mer | 6×3RL; 2×NA; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Glu92Pro Mutant | homo-4-mer | 4×PO4; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A97S at pH 5.4 | homo-4-mer | 8×GOL; | ||||
| Assess | ||||||
| Transthyretin in complex with 4-(1,3-Benzothiazol-2-yl)-2-methylaniline | homo-4-mer | 4×BM8; | ||||
| Assess | ||||||
| Crystal structure of Transthyretin complexed with pterostilbene | homo-4-mer | 4×SO4; 6×DMS; 2×3RL; | ||||
| Assess | ||||||
| Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker). | homo-4-mer | 2×JZE; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenol | homo-4-mer | 4×IW3; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in Apo-form | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with L6 | homo-4-mer | 4×L6Y; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide | homo-4-mer | 4×LJ5; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin | homo-4-mer | |||||
| Assess | ||||||
| Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoaniline | homo-4-mer | 4×IW4; | ||||
| Assess | ||||||
| Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenol | homo-4-mer | 4×IW2; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Ser85Pro/Glu92Pro Mutant | homo-4-mer | 4×NA; 2×GOL; 4×PEG; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (E)-3-(((3,5-dibromo-2-hydroxybenzylidene)amino)oxy)propan… | homo-4-mer | 4×ND5; 2×GOL; 4×PGO; | ||||
| Assess | ||||||
| Transthyretin complexed with (E)-4-(2-(naphthalen-1-yl)vinyl)benzene-1,2-diol | homo-4-mer | 4×9RJ; 2×GOL; 2×NA; | ||||
| Assess | ||||||
| X-ray crystal structure of V30M-TTR in complex with resveratrol | homo-4-mer | 4×STL; 2×NA; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazole | homo-4-mer | 4×MR6; | ||||
| Assess | ||||||
| Transthyretin complexed with (E)-4-(2-(naphthalen-2-yl)vinyl)benzene-1,2-diol | homo-4-mer | 4×9PS; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Val30Met Mutant in Complex with Tafamidis | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| Crystal structure of Cys10 sulfonated transthyretin | homo-4-mer | 2×SO4; | ||||
| Assess | ||||||
| Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloroph… | homo-4-mer | 4×0U7; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker) | homo-4-mer | 2×44C; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline | homo-4-mer | 4×IW5; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin with bromide in complex with alpha-mangostin | homo-4-mer | 4×MKS; 12×BR; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acid | homo-4-mer | 4×ROA; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Asp38Ala Mutant in Complex with Diflunisal | homo-4-mer | 4×1FL; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Asp38Ala Mutant | homo-4-mer | 2×ACT; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin with bromide in complex with gamma-mangostin | homo-4-mer | 4×MKT; 16×BR; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazole | homo-4-mer | 4×MR5; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Val30Met/Thr119Met Mutant | homo-4-mer | 2×PEG; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6 | homo-4-mer | 4×AJU; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene | homo-4-mer | 4×LJ1; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl | homo-4-mer | 4×LJ3; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A97S at pH 7.6 | homo-4-mer | |||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxy… | homo-4-mer | 4×FBC; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with Benzbromarone | homo-4-mer | 4×R75; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Thr119Tyr Mutant | homo-4-mer | 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of WT-TTR in complex with bithionol | homo-4-mer | 2×B1T; 4×CA; | ||||
| Assess | ||||||
| The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phe | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acid | homo-4-mer | 4×DIU; | ||||
| Assess | ||||||
| Human Transthyretin expressed in Vibrio natriegens | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of Transthyretin mutant I84S at acidic pH | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of H88A mutated human transthyretin | homo-4-mer | 2×MPD; 1×MG; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with naringenin derivative-14 | homo-4-mer | 4×90Q; 4×CA; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Leu55Pro Mutant in Complex with Tafamidis | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carbox… | homo-4-mer | 4×26C; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin | homo-4-mer | 6×CA; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Thr119Met Mutant | homo-4-mer | |||||
| Assess | ||||||
| Structure of Human Transthyretin Asp38Ala Mutant in Complex with Tafamidis | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimi… | homo-4-mer | 8×3M2; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl ester | homo-4-mer | 4×PWF; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Asp38Ala/Thr119Met Mutant | homo-4-mer | 4×GOL; 2×SO4; 4×ACT; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6 | homo-4-mer | 4×O4B; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker) | homo-4-mer | 2×6CA; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Thr119Trp Mutant | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of human transthyretin | homo-4-mer | 4×MG; | ||||
| Assess | ||||||
| Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenol | homo-4-mer | 4×IW1; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BI… | homo-4-mer | 4×3CA; | ||||
| Assess | ||||||
| Crystal Structure of Transthyretin in Complex With Ligand C-6 | homo-4-mer | 4×42M; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1 | homo-4-mer | 4×4V2; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with dasatinib | homo-4-mer | 4×1N1; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A97S complexed with Tolcapone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Crystal structure of human Transthyretin (TTR) at pH 4.0 | homo-4-mer | |||||
| Assess | ||||||
| TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS | homo-4-mer | |||||
| Assess | ||||||
| Structure of Wild Type Human Transthyretin in Complex with Tafamidis | homo-4-mer | 4×3MI; | ||||
| Assess | ||||||
| The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin … | homo-4-mer | 4×DNF; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Ala108Trp Mutant | homo-4-mer | 2×CL; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor … | homo-4-mer | 4×7BD; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with glabridin | homo-4-mer | 4×GBJ; | ||||
| Assess | ||||||
| Structure of Human Transthyretin Val30Met Mutant in Complex with Diflunisal | homo-4-mer | 4×1FL; 2×ACT; | ||||
| Assess | ||||||
| V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5 | homo-4-mer | |||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibi… | homo-4-mer | 4×8BD; | ||||
| Assess | ||||||
| Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',… | homo-4-mer | 4×PCQ; | ||||
| Assess | ||||||
| The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrol | homo-4-mer | 2×SO4; 4×DES; 2×GOL; | ||||
| Assess | ||||||
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl ester | homo-4-mer | 4×QAP; | ||||
| Assess | ||||||
| Crystal Structure of Human Transthyretin Leu55Pro Mutant | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3 | homo-4-mer | 4×FT2; | ||||
| Assess | ||||||
| Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene | homo-4-mer | 4×LJ4; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH | homo-4-mer | 4×IFB; | ||||
| Assess | ||||||
| Crystal structure of human Transthyretin with bound iodide | homo-4-mer | 12×IOD; | ||||
| Assess | ||||||
| Crystal structure of A97S transthyretin | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7 | homo-4-mer | 4×43F; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with triclabendazole | homo-4-mer | 4×JA9; | ||||
| Assess | ||||||
| The monoclinic crystal structure of transthyretin in complex with diethylstilbestrol | homo-4-mer | 2×ACT; 2×DMS; 2×GOL; 2×DES; | ||||
| Assess | ||||||
| Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMe | homo-4-mer | 4×IFA; | ||||
| Assess | ||||||
| Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5 | homo-4-mer | 4×GEN; | ||||
| Assess | ||||||
| Human transthyretin (ttr) complexed with diflunisal | homo-4-mer | 4×1FL; | ||||
| Assess | ||||||
| Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4'… | homo-4-mer | 4×NE1; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2 | homo-4-mer | 4×FT1; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate | homo-4-mer | 4×2AN; | ||||
| Assess | ||||||
| Crystal structure of Transthyretin variant A97S in monomeric form | homo-4-mer | 2×MPD; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with dichlorophen | homo-4-mer | 4×JAL; 2×CA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACID | homo-4-mer | 2×DBF; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFEN | homo-4-mer | 2×FLP; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID | homo-4-mer | 2×OFL; | ||||
| Assess | ||||||
| Crystal structure of Transthyretin mutant I84A at low pH | homo-4-mer | |||||
| Assess | ||||||
| Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker… | homo-4-mer | 4×JZD; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICA… | homo-4-mer | 2×BPD; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A97S complexed with Diflunisal | homo-4-mer | 4×1FL; | ||||
| Assess | ||||||
| Structure of Wild Type Human Transthyretin in Complex with Diflunisal | homo-4-mer | 4×1FL; 4×CA; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with naringenin derivative-18 | homo-4-mer | 4×91C; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL | homo-4-mer | 2×STL; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATURE | homo-4-mer | 12×BME; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN | homo-4-mer | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAC | homo-4-mer | 2×DIF; | ||||
| Assess | ||||||
| The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin … | homo-4-mer | 4×DNF; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin complexed with glabridin | homo-4-mer | 4×GBJ; 2×CA; | ||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pH | homo-4-mer | |||||
| Assess | ||||||
| An Engineered Transthyretin Monomer that is Non-amyloidogenic - Unless Partially Denatured | homo-4-mer | |||||
| Assess | ||||||
| Cryo-EM structure of cardiac amyloid fibril from a variant ATTR I84S amyloidosis patient-3, variant… | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of I73L mutated human transthyretin | homo-4-mer | 4×MG; | ||||
| Assess | ||||||
| Crystal structure of Transthyretin in complex with a covalent inhibitor trans-styrylpyrazole | homo-4-mer | 4×XHF; 4×XHB; | ||||
| Assess | ||||||
| Crystal structure of H88S mutated human transthyretin | homo-4-mer | |||||
| Assess | ||||||
| X-ray crystal structure of human Transthyretin at room temperature | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of human Transthyretin (TTR) at pH3.5 | homo-4-mer | |||||
| Assess | ||||||
| Crystal structure of P113A mutated human transthyretin | homo-4-mer | 4×SO4; 4×CL; | ||||
| Assess | ||||||
| Crystal structure of H88Y mutated human transthyretin | homo-4-mer | 4×SO4; 4×CL; | ||||
| Assess | ||||||
| TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS | homo-4-mer | |||||
| Assess | ||||||
| Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-… | homo-4-mer | 4×NE2; | ||||
| Assess | ||||||
| V122I Transthyretin structure in complex with Tolcalpone | homo-4-mer | 4×TCW; | ||||
| Assess | ||||||
| Crystal structure of H88F mutated human transthyretin | homo-4-mer | 4×SO4; | ||||
| Assess | ||||||
| HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]… | homo-4-mer | 4×FLF; | ||||
| Assess | ||||||
| Neutron crystal structure of human Transthyretin | homo-4-mer | |||||
| Assess | ||||||
| a covalent dimer of transthyretin that affects the amyloid pathway | homo-4-mer | |||||
| Assess | ||||||
| THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-… | homo-2-mer | 2×T44; | ||||
| Assess | ||||||
| TRANSTHYRETIN COMPLEX WITH RETINOIC ACID | homo-2-mer | 2×9CR; | ||||
| Assess | ||||||
| THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30-… | homo-2-mer | 2×T44; | ||||
| Assess | ||||||
| TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT | homo-2-mer | |||||
| Assess | ||||||
| Transthyretin natural mutant A19D | homo-2-mer | 1×CA; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin variant A25T in complex with flufenamic acid. | homo-2-mer | 2×FLF; | ||||
| Assess | ||||||
| TRANSTHYRETIN THR119MET PROTEIN STABILISATION | homo-2-mer | 2×T44; | ||||
| Assess | ||||||
| Crystal structure of human transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carboxylic ac… | homo-2-mer | 2×CA; 2×J5R; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with 6-hydroxy BID | homo-2-mer | 2×PKK; | ||||
| Assess | ||||||
| Crystal structure of V30M mutated transthyretin in complex with 8-chloro-9-oxo-9H-xanthene-3-carbox… | homo-2-mer | 2×CA; 2×J5R; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with 6-hydroxy BBM | homo-2-mer | 2×PKQ; | ||||
| Assess | ||||||
| Human transthyretin (TTR) complexed with Benzoxazole | homo-2-mer | 2×205; | ||||
| Assess | ||||||
| Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic aci… | homo-2-mer | 2×1BD; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with BBM | homo-2-mer | 2×R75; 1×CA; | ||||
| Assess | ||||||
| Crystal structure of V30M-TTR in complex with BID | homo-2-mer | 2×PJO; | ||||
| Assess | ||||||
| STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFI… | homo-2-mer | |||||
| Assess | ||||||
| HUMAN TRANSTHYRETIN (PREALBUMIN) | homo-2-mer | |||||
| Assess | ||||||
| Solution structure of the T119M variant of transthyretin in its monomeric state | monomer | |||||
| Assess | ||||||
| Solution structure of the F87M/L110M variant of transthyretin in the monomeric state | monomer | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 1kgj.1.A | homo-4-mer | 0.86 | 2×FL8; | 83.33 | ||
| Assess | ||||||